Proactive Investors - Run By Investors For Investors

Osprey Medical attracts $10 million from investment manager Allan Gray

The company is aiming to raise a further $10.5 million from a non-renounceable entitlement offer.
Osprey has achieved consistent quarterly unit sales growth

Osprey Medical Inc (ASX:OSP) has raised $10 million via a private placement to Allan Gray, a leading South Africa based investment management firm.

The company has issued about 64 million CHESS Depositary Interests (CDIs) (representing about 32 million Osprey shares) to Allan Gray at 15.5 cents per CDI.


In addition to the placement, Osprey is offering existing holders of CDIs in Australia, New Zealand, Hong Kong and Singapore the opportunity to participate in a pro-rata non-renounceable entitlement offer.

Eligible holders will have the opportunity to subscribe for one new CDI for every five CDIs held by them at an offer price of 15.5 cents per CDI.

Osprey is aiming to raise a maximum of about $10.5 million from the entitlement offer.


Osprey is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures.

The company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design.

Quarterly DyeVert sales

In July 2018, Osprey revealed three contracts with leading GPOs (group purchasing organisation) in the US covering around 10% of the addressable market for Osprey’s DyeVert products.

GPOs represent some of the largest networks of hospitals and healthcare providers in the US.

In October 2018, Osprey received an award from Premier, Inc., one of the largest GPOs in the US.

View full OSP profile View Profile

Osprey Medical Ltd Timeline

Related Articles

November 08 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use